Role of Small-Molecule Myosin Inhibitors in oHCM Treatment
James L. Januzzi, MD, provides insight on the pathophysiology of obstructive hypertrophic cardiomyopathy (oHCM) and comments on small-molecule myosin inhibitors as an emerging therapeutic option.
Source: hcplive.com